Heartseed Inc. [219A.T]

TOKYO, May 15 (Pulse News Wire) – Heartseed Inc. (219A.T) reported a lower net profit of ¥58.2 million for the quarter ending March 31, 2026, compared to a loss of -¥478 million in the same period last year.

Revenue was not disclosed due to recent changes in the fiscal year structure. During the quarter, Heartseed continued development of its lead pipeline program HS-001, which uses allogeneic iPS cell-derived cardiac muscle cells to treat heart failure patients. Clinical trial data collection progressed smoothly, with plans to initiate patient treatment for another program, HS-005, in the upper half of 2026.

Financially, total assets decreased by ¥10.7 million to ¥7.142 billion, while liabilities fell by ¥1.46 million to ¥1.61 billion. Equity dropped by ¥47.9 million to ¥7.142 billion primarily due to the recorded quarterly loss. Heartseed also revised its performance forecast due to foreign exchange impacts, though specifics were not detailed in the release.

The company did not announce any dividend payments for the current or upcoming fiscal year.

Financial results — FY2026/12 (consolidated)

MetricCurrentYoY
Revenue¥465Mn/a
Operating profit¥-75Mn/a
Net profit¥-58Mn/a

Next period forecast

Revenue

¥467M

n/a

Op. profit

¥-2,207M

n/a

Net profit

¥-2,158M

n/a

Source: TDNet filing · Figures in millions of yen

Original Disclosure (PDF)

🟢 Confidence: High AI-translated content.